The medical industry watches with trepidation as mifepristone case could have huge consequences for drug regulation
Jessica Glenza in New York
Mon 25 Mar 2024
A supreme court case about one little pill – mifepristone – has the medical and pharmaceutical world on edge. … Despite a more than 20-year track record of safe real-world use, backed up by more than 100 peer-reviewed studies, a group of anti-abortion doctors is seeking to roll back US Food and Drug Administration (FDA) decisions that changed and relaxed some prescribing rules.
If the doctors succeed, despite contested and in some cases now-retracted evidence of harm, the case could reshape abortion access in the US and have enormous and unpredictable consequences for how drugs are prescribed, regulated and developed.
Continued: https://www.theguardian.com/us-news/2024/mar/25/abortion-pill-case-fda